Bayer AG NA - Asset Resilience Ratio
Bayer AG NA (BAYN) has an Asset Resilience Ratio of 7.10% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Bayer AG NA's Asset Resilience Ratio has changed over time. Check BAYN capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Bayer AG NA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Bayer AG NA market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €6.67 Billion | 6.03% |
| Short-term Investments | €1.19 Billion | 1.07% |
| Total Liquid Assets | €7.86 Billion | 7.10% |
Asset Resilience Insights
- Limited Liquidity: Bayer AG NA maintains only 7.10% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Bayer AG NA Industry Peers by Asset Resilience Ratio
Compare Bayer AG NA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.29% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 0.08% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.10% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
Annual Asset Resilience Ratio for Bayer AG NA (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Bayer AG NA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.10% | €7.86 Billion ≈ $9.18 Billion |
€110.61 Billion ≈ $129.31 Billion |
-0.19pp |
| 2024-12-31 | 7.30% | €8.09 Billion ≈ $9.45 Billion |
€110.85 Billion ≈ $129.60 Billion |
-1.81pp |
| 2023-12-31 | 9.11% | €10.59 Billion ≈ $12.38 Billion |
€116.26 Billion ≈ $135.92 Billion |
+0.98pp |
| 2022-12-31 | 8.13% | €10.15 Billion ≈ $11.87 Billion |
€124.88 Billion ≈ $145.99 Billion |
+1.69pp |
| 2021-12-31 | 6.44% | €7.74 Billion ≈ $9.05 Billion |
€120.24 Billion ≈ $140.57 Billion |
-3.72pp |
| 2020-12-31 | 10.15% | €11.88 Billion ≈ $13.89 Billion |
€117.05 Billion ≈ $136.84 Billion |
+5.87pp |
| 2019-12-31 | 4.28% | €5.40 Billion ≈ $6.32 Billion |
€126.26 Billion ≈ $147.61 Billion |
+0.85pp |
| 2018-12-31 | 3.43% | €4.34 Billion ≈ $5.07 Billion |
€126.28 Billion ≈ $147.64 Billion |
-8.68pp |
| 2017-12-31 | 12.12% | €9.10 Billion ≈ $10.64 Billion |
€75.09 Billion ≈ $87.78 Billion |
+5.52pp |
| 2016-12-31 | 6.60% | €5.42 Billion ≈ $6.34 Billion |
€82.24 Billion ≈ $96.14 Billion |
+6.23pp |
| 2015-12-31 | 0.37% | €272.00 Million ≈ $318.00 Million |
€73.92 Billion ≈ $86.42 Billion |
+0.15pp |
| 2014-12-31 | 0.22% | €154.00 Million ≈ $180.04 Million |
€70.23 Billion ≈ $82.11 Billion |
-0.05pp |
| 2013-12-31 | 0.27% | €138.00 Million ≈ $161.34 Million |
€51.32 Billion ≈ $59.99 Billion |
-0.39pp |
| 2012-12-31 | 0.66% | €339.00 Million ≈ $396.33 Million |
€51.34 Billion ≈ $60.02 Billion |
-4.62pp |
| 2011-12-31 | 5.28% | €2.78 Billion ≈ $3.25 Billion |
€52.77 Billion ≈ $61.69 Billion |
+3.32pp |
| 2010-12-31 | 1.96% | €1.01 Billion ≈ $1.18 Billion |
€51.51 Billion ≈ $60.22 Billion |
+1.24pp |
| 2009-12-31 | 0.72% | €367.00 Million ≈ $429.06 Million |
€51.04 Billion ≈ $59.67 Billion |
-0.49pp |
| 2008-12-31 | 1.21% | €634.00 Million ≈ $741.21 Million |
€52.51 Billion ≈ $61.39 Billion |
+0.56pp |
| 2007-12-31 | 0.65% | €335.00 Million ≈ $391.65 Million |
€51.38 Billion ≈ $60.07 Billion |
+0.53pp |
| 2006-12-31 | 0.12% | €69.71 Million ≈ $81.50 Million |
€55.89 Billion ≈ $65.34 Billion |
-0.51pp |
| 2005-12-31 | 0.64% | €233.03 Million ≈ $272.44 Million |
€36.69 Billion ≈ $42.90 Billion |
+0.56pp |
| 2004-12-31 | 0.08% | €28.77 Million ≈ $33.63 Million |
€37.78 Billion ≈ $44.16 Billion |
-0.27pp |
| 2003-12-31 | 0.34% | €128.63 Million ≈ $150.39 Million |
€37.38 Billion ≈ $43.70 Billion |
+0.28pp |
| 2002-12-31 | 0.07% | €28.59 Million ≈ $33.42 Million |
€41.73 Billion ≈ $48.79 Billion |
-0.07pp |
| 2001-12-31 | 0.14% | €51.70 Million ≈ $60.44 Million |
€37.10 Billion ≈ $43.38 Billion |
-0.45pp |
| 2000-12-31 | 0.59% | €214.01 Million ≈ $250.20 Million |
€36.55 Billion ≈ $42.73 Billion |
-- |
About Bayer AG NA
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; speci… Read more